Dharmacon has become an important resource for those investigating the mechanisms of siRNA (small interfering RNA)-induced gene knockdown and applying the specificity and potency of RNAi to human biotherapeutics.
[4] The conditional requirement was the divestment of Thermo Fisher Scientific's cell culture (sera and media), magnetic beads and Dharmacon gene modulation businesses for antitrust reasons.
In early January 2014, GE Healthcare reached an agreement with Thermo Fisher Scientific to acquire the cell culture, magnetic bead and Dharmacon gene modulation businesses for US$1.05 billion.
In the fall of 2014, GE Healthcare announced it had reached a licensing agreement with the Broad Institute of MIT and Harvard granting access to CRISPR-Cas9 intellectual property.
[7] In July 2015, GE Healthcare Dharmacon launched synthetic crRNA and lentiviral sgRNA pre-designed with a functionally validated algorithm against entire human, mouse and rat genomes.